<mz class="zvhpyku"></mz>

AG尊龙

Be the most trusted biotech company

2020-10-29

The Results of the Phase 3 Study of Henlius’ Adalimumab Biosimilar HLX03 Presented on EADV 2020
2020-10-15

Henlius and Essex Enter into a Global Co-Development and Exclusive License Agreement, to Jointly Develop Bevacizumab to Treat Ophthalmic Diseases
2020-10-05

Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA
2020-09-30

Henlius Granted Exclusive Development and Commercialisation Rights of HLX02 in the US and Canada to Accord
2020-09-30

Mr. Wenjie Zhang Appointed as the CEO of Henlius to Keep Innovating in Operation Management Models and Implementing the Global Strategy
2020-09-20

Henlius Released Phase 3 Study Data of its Bevacizumab Biosimilar HLX04 at CSCO 2020
2020-09-20

First patient dosed in phase 1 clinical trial of Henlius pertuzumab biosimilar HLX11
2020-09-17

Scientific Innovation for the Benefit of the Patients -Exclusive Interview with Henlius Co-CSO and Senior Vice President of R&D, Dr. Ningshu Liu
2020-09-17

The Updated Multi-Centre Phase 3 Clinical Study Data of Trastuzumab 汉曲优® Released in ESMO